Podcasts about wegovy

GLP-1 drugs like Ozempic and Wegovy are changing more than just waistlines—they're disrupting the grocery aisle. JMR Co-Editor Brett Gordon speaks with Sylvia Hristakeva (Cornell), Jura Liaukonyte (Cornell), and Leo Feller (Numerator) about their paper, "The No Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand.” The study linked GLP-1 usage survey data to 150,000 households' purchase data, finding that grocery spending declines by approximately 5% within six months, concentrated in processed, calorie-dense categories. Spending reverts to pre-adoption levels upon stopping the medication. In the episode, you'll hear how quickly the project came together and the challenges of working on such a high-profile topic.Paper on SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5073929Paper at JMR: https://journals.sagepub.com/doi/10.1177/00222437251412834

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX     A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX   A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries.   Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make "false or misleading" claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process." https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX   Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical's facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical's products.  Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May.   https://www.medtechdive.com/news/fda-warns-insulin-infusion-set-maker-unomedical-over-leaks-mishandled-comp/813503/ XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025.   Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications.   Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin.   Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits.   The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control.   Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders.   The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible.   Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes," says Dr. Jennifer Snaith, endocrinologist and co-lead of the study.   https://scitechdaily.com/groundbreaking-trial-reveals-unexpected-benefit-of-metformin-in-type-1-diabetes/   Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it's secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic  acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors.   https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he'd stepped away for a medical leave. Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer's return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well.     https://www.drugdeliverybusiness.com/kevin-sayer-returns-dexcom-board-chair/ SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement.   Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google's hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016.   https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel's proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care's Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year.   Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025.   Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/

March 10, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Novo Nordisk drops patent case against Hims & Hers as companies reach agreement for Hims to offer FDA-approved Ozempic and Wegovy at standard pricing Whoop introduces hormone biomarker testing for 11 hormonal markers combined with wearable data and AI-driven insights as women become fastest-growing user segment Fitt Insider releases Scouting Report highlighting 50 early-stage startups shaping wellness across mental, physical, social, environmental, and existential health Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

The first episode of Skinny Inc. was all about the science behind GLP-1s, and the second episode was about the business, from the pharmaceutical companies who make GLP-1s to the insurance plans that may or may not cover it. Today, we're exploring how the so-called “Ozempic era,” affects people's mental health. First, business owner Maiyhet Burton tells us how using a GLP-1 has helped her body image. Globe health reporter Kelly Grant details how experts are split on the effect of GLP-1s on weight stigma, and psychotherapist Zoë Bisbing explains how the body positive movement helps her clients. Plus, Tigress Osborn, executive director of the National Association to Advance Fat Acceptance on why the popularity of GLP-1s shows how far we have to go with anti-fat discrimination, and Ary Mahraj and Emily Donahue from the National Eating Disorder Information Centre tell us how people with eating disorders may be impacted by the constant discussions about weight loss. Finally, Dr. Stephen Glazer, Medical Director for the Bariatric Surgical Program at Humber River Hospital in Toronto on how weight stigma can be internalized. You can contact the National Eating Disorders Information Centre at their toll-free helpline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you're on Wegovy, Zepbound, Ozempic, or Mounjaro — and worried about what happens when you stop — this episode is for you. The fear of gaining it all back is real. But weight regain is not inevitable. It's manageable. And I'm going to show you how. "What happens when you stop your GLP-1?" This is one of the most common questions I get in my clinic every single week. It's time I answered it publicly — with science, not fear. In this episode, I break down exactly what happens in your body when you stop your GLP-1, why weight regain happens, and the five pillars you need to protect your results, whether you're stopping by choice or out of necessity. Listen now! Episode Highlights: The physiological reason hunger surges and metabolism slows when you stop GLP-1s  What the SURMOUNT-4 clinical trial tells us about weight regain after stopping Tirzepatide Who is at highest risk for regaining weight  The 5 pillars of weight maintenance: protein, resistance training, carb awareness, appetite retraining, and medication transition strategy Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Welcome to Ozempic Weightloss Unlocked, the podcast where we decode what this powerful medication really means for your body, your health, and your everyday life.Today we are diving into the most important new research about Ozempic and other glucagon like peptide one weight loss drugs. These medicines were first used for diabetes, but they have rapidly become some of the most talked about tools for weight management and even heart health.According to the University of Cambridge, people who stop glucagon like peptide one drugs such as Ozempic and Wegovy regain, on average, about sixty percent of the weight they lost within one year of stopping. By around sixty weeks, the regain begins to level off and is projected to reach about seventy five percent of the lost weight. That means roughly a quarter of the original weight loss may stay off long term, even after the drug is stopped.Researchers suggest there are a few possible reasons. For some people, time on Ozempic seems to reset eating habits, like smaller portions and more balanced meals, and those behaviors can stick. There may also be longer lasting changes in hunger hormones and how the brain regulates appetite. But scientists still do not know exactly how much of the regained weight is fat versus muscle. Early data suggest that as much as forty to sixty percent of weight lost on these drugs can be lean mass, including muscle, and it is not yet clear if that muscle comes back in the same way.While the injectables have been the focus for years, the Association of American Medical Colleges reports that new glucagon like peptide one weight loss pills were prescribed to about one hundred seventy thousand people in the first three weeks after their United States launch in early twenty twenty six. Trial data from Novo Nordisk show that people taking the oral version with diet and activity changes lost about thirteen percent of their body weight over a little more than a year, compared with about fifteen to sixteen percent with injectable Wegovy. In practice, doctors say the results are broadly similar, and the big difference is convenience and preference. Some people find a pill easier than a weekly injection, even though the pill has strict empty stomach rules.Public health researchers at Johns Hopkins University report that glucagon like peptide one drugs lead to meaningful weight loss across age, race, and starting weight groups, although women in their study lost a somewhat higher percentage of body weight than men. At the population level, a recent Gallup poll cited by the Association of American Medical Colleges found that obesity rates in the United States have dipped slightly since these drugs became more common, suggesting they may already be shifting public health trends.At the same time, doctors are sounding a note of caution. The Association of American Medical Colleges highlights concerns about side effects, unequal access, and what happens when people use these medicines long term for many different conditions. Some clinicians are seeing new or worsened eating disorders, where people become intensely fearful of any weight regain after starting Ozempic. Others are worried about the possibility of losing too much muscle and what that might mean for strength, metabolism, and aging.The message from obesity and endocrine specialists is that Ozempic works best as part of a full plan, not a stand alone fix. That means nutrition support, resistance exercise to protect muscle, realistic expectations about possible weight regain if the drug is stopped, and an individualized decision about whether treatment should be short term or ongoing.On future episodes of Ozempic Weightloss Unlocked, we will explore mental health effects, muscle versus fat loss, and how these medications are being studied for conditions like heart disease, liver disease, and even addiction.Thank you for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe so you never miss an update on the science and real life impact of Ozempic and related medications.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic and similar weight loss drugs have dominated health headlines again this week, and much of the conversation is circling around how these medications are reshaping expectations about body size, long term health, and even celebrity image. Ozempic, whose generic name is semaglutide, is part of a class of drugs called glucagon like peptide one receptor agonists that were first approved to help people with type two diabetes manage blood sugar. In recent years doctors have also prescribed them for weight loss, leading to sharp demand, ongoing debates about shortages for diabetes patients, and questions about long term safety. Over the past week, news outlets and medical commentators have been focusing on three main themes. First, they are tracking how quickly public perception has shifted from viewing these drugs as last resort options to seeing them as mainstream tools, especially in the United States and Europe where prescriptions continue to rise. Second, they are highlighting new calls from endocrinologists and obesity specialists for more careful monitoring of side effects like nausea, vomiting, loss of muscle mass, and possible mood changes, particularly when the drugs are used for cosmetic reasons rather than clear medical need. Third, policy experts are discussing how health systems and insurers will handle the ongoing costs of long term treatment, since many people regain weight when they stop taking the medication and may need to stay on it for years. All of this is playing out while high profile figures are becoming real time case studies in how society reacts to visible weight loss. Oprah Winfrey is at the center of that conversation again this week after her appearances at Paris Fashion Week. Outlets such as the Times of India and entertainment platforms in North America reported that her noticeably slimmer frame at the Stella McCartney and Chloe shows reignited public debate about glucagon like peptide one weight loss drugs, including Ozempic and Wegovy, the higher dose version approved specifically for obesity. These reports noted that Oprah has previously acknowledged using weight loss medication as one tool in a broader plan that also includes portion control, daily movement, and a more structured relationship with food. Commentators pointed out that she has stopped framing medication as a moral failure and instead describes it as a science based option for people who have struggled with weight for decades. At the same time, newer coverage this week has emphasized how harsh the online reaction has been. Some social media users accused her of taking Ozempic to an extreme, while others suggested she looked too thin or even questioned whether videos of her in Paris were real. Articles from sources such as Atlanta Black Star highlighted how Oprah appears publicly unfazed by this chatter, focusing on her confidence, her ease in interviews, and her willingness to show ordinary moments like laughing with Gayle King over tight pants in the back of a car. The contrast is striking. On one side, there is a swirl of conspiracy theories and body shaming, including comments that label her and other celebrities as so called Ozempic victims. On the other, there are medical voices urging listeners to view these drugs through a clinical lens instead of a gossip lens, reminding everyone that obesity is a chronic disease and that treatments like semaglutide can lower risks of heart disease and diabetes when used appropriately and monitored by a physician. For listeners following the story this week, the key takeaway is that Ozempic and related drugs are not magic fixes or moral shortcuts. They are powerful medications with real benefits and real risks, now being tested in the very public arena of celebrity culture. Oprah Winfrey, after years of scrutiny about her weight, is once again a focal point, but this time she is using her platform to push the idea that seeking medical help for weight is no different from taking medication for blood pressure or cholesterol. As coverage over the last few days has shown, the real challenge may be less about the science of these drugs and more about whether society can talk about weight, health, and appearance without sliding back into shame and stigma. Thank you for listening, and come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

GLP-1 drugs like Ozempic, Wegovy, and semaglutide are everywhere right now and so is the fear surrounding them. Are they dangerous? Are they a breakthrough? And why is the internet so divided?Today I'm joined by Drs. Mark and Michele Sherwood from the Functional Medical Institute to talk honestly about what GLP-1s actually do, who they're designed to help, and why so much of the conversation online is driven by hype and fear instead of facts.We also dive into ketones, blood sugar and mood swings in kids, snoring and sleep apnea, hormones for men in their 40s, cold plunges and saunas, and why so many people are struggling with anxiety right now. Most importantly, we talk about how to become “hope dealers” in a culture that profits from fear.If you're looking for clear thinking, practical health wisdom, and encouragement in a noisy world, this episode is for you.Prime Sponsor: No matter where you live, visit the Functional Medical Institute online today to connect with Drs Mark and Michele Sherwood. Go to homeschoolhealth.com to get connected and see some of my favorites items. Use coupon code HEIDI for 20% off!Show mentions: http://heidistjohn.com/mentionsWebsite | heidistjohn.comSupport the show! | donorbox.org/donation-827Rumble | rumble.com/user/HeidiStJohnYoutube | youtube.com/@HeidiStJohnPodcastInstagram | @‌heidistjohnFacebook | Heidi St. JohnX | @‌heidistjohnFaith That Speaks Online CommunitySubmit your questions for Fan Mail Friday | heidistjohn.com/fanmailfriday

Howie and Harlan are joined by Yale School of Medicine neurologist Kevin Sheth to discuss how collaboration helps drive breakthroughs in brain health, including advances in detecting stroke and other neurological diseases earlier and more precisely. Harlan reflects on lessons from his family's recent experience navigating the healthcare system; Howie examines the expanding marketplace for GLP-1 weight-loss drugs and the challenges of ensuring safe and appropriate use. Show notes: The Family Perspective Cleveland Clinic: Percutaneous Coronary Intervention "What's the Difference Between a CCU and an ICU?" Kevin Sheth Alva Health Mayo Clinic: Stroke Video: Kevin Sheth at the Yale Innovation Summit Sandra Saldana, PhD, MBA "Buddy System"  NIH: Multiple Principal Investigators "Assessing the Decade of the Brain" "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease" Kevin Sheth: "Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019"  Endovascular Thrombectomy (EVT) Ischemic vs Hemorrhagic Stroke "What is cognitive reserve?"  Cheaper Obesity Drugs "Will Novo Nordisk's slashing of obesity drug prices save patients' money? It depends"  "Novo Nordisk to halve US list price of Wegovy from 2027"  "Walgreens Virtual Healthcare Adds Weight Management Services to Support Patients on Their Weight Loss Journey"  In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Dietitians Aidan Muir and Torwen Eerkens break down GLP-1 medications for weight loss: the different types available; potential benefits and risks; and what to consider for nutrition to optimise health while using GLP-1s. (1:25) What are GLP-1 Medications? (3:53) History of Medications (8:49) Torwen & Aidan's Philosophy on GLP-1s (13:04) Nutrition Considerations for GLP-1 Use (19:25) Supplements to Consider WEBSITE:  https://www.idealnutrition.com.au/ PODCAST:  https://www.idealnutrition.com.au/podcast/ INSTAGRAM:  https://www.instagram.com/idealnutrition__/?hl=en Our dietitians

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the pharmaceutical and biotech industries. The landscape continues to evolve with scientific breakthroughs, regulatory hurdles, and strategic alliances that have profound implications for drug development and patient care.Let's begin with Novo Nordisk's substantial investment of $500 million into an Ireland-based plant. This move reflects the ongoing demand for obesity treatments like Wegovy, a GLP-1 receptor agonist known for its efficacy in diabetes and weight management. The expansion aims to enhance production capabilities, particularly for markets outside the US, highlighting the global demand for such therapies. Recent studies in rodents suggest that GLP-1 medications may also support heart attack recovery by relaxing blood vessels, indicating broader cardiovascular benefits. This illustrates the multifaceted potential of GLP-1 receptor agonists beyond their primary indications.Turning to regulatory developments, the FDA has issued complete response letters to AstraZeneca and GSK, citing deficiencies in their data submissions. The feedback questions the data integrity of AstraZeneca's Saphnelo and the efficacy of GSK's Exdensur. These letters emphasize the importance of robust clinical evidence for achieving regulatory approval, underscoring the FDA's stringent standards. Such regulatory scrutiny highlights the necessity for pharmaceutical companies to ensure comprehensive and transparent data presentation.In strategic maneuvers within the industry, Esperion Therapeutics has acquired Corstasis Therapeutics for over $75 million, bringing the newly FDA-approved nasal spray Enbumyst into its portfolio. This acquisition illustrates ongoing consolidation trends aimed at diversifying product offerings and strengthening market positions in an increasingly competitive landscape.Meanwhile, DISC Medicine's decision to lay off 20% of its workforce following the FDA's rejection of a rare disease drug candidate underscores the volatility and risk inherent in drug development. This highlights the financial and operational challenges biotechs face when navigating complex regulatory pathways.Novo Nordisk and BioMarin have received FDA label expansions, allowing them to reach broader patient populations or offer additional therapeutic indications. Such expansions are crucial for enhancing treatment access and driving company growth. However, these advancements also reflect the challenges companies face in meeting evolving regulatory expectations while striving to expand their market footprint.Geopolitical tensions impact the industry as well, with companies closely monitoring employee safety and supply chain stability amid conflicts in regions like the Middle East. This situation highlights the vulnerabilities of global operations and underscores the need for robust contingency planning to maintain medicine access during crises.On the innovation front, Kyowa Kirin has discontinued its late-stage autoimmune disease program following cancer concerns linked to its anti-OX40 monoclonal antibody. This decision reflects the complexities of balancing innovative research with patient safety considerations. The discontinuation followed new cancer cases among participants receiving an anti-OX40 monoclonal antibody treatment, emphasizing the critical need for robust safety monitoring throughout the development process.Theravance Biopharma's substantial downsizing reflects similar challenges after a failed phase 3 trial for a blood pressure disorder drug led to significant corporate restructuring. This highlights how clinical setbacks can profoundly impact corporate strategy and employee livelihoods, serving as cautionary tales about resource investments required inSupport the show

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?Produced and presented by Sam FenwickIf you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukBusiness Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Photo: A man gets his waist measured. Credit: Getty Images)

Send a textEpisode Summary (Short Version):This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compounded semaglutide, to Walgreens and Amazon launching cash-pay weight loss clinics.As insurance denials continue and out-of-pocket costs rise, patients are stuck between a shifting policy landscape and a growing direct-to-consumer market. Plus, an AI-designed oral GLP-1 enters Phase 3 trials, signaling how fast obesity medicine is evolving.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Rubicon - James explains Risk Adjustment to the SiriusXM audience

A Dutch museum has confirmed a newly rediscovered Rembrandt, thanks to a microscopic study that uncovered the artist’s signature touch a single, tiny brushstroke hidden like a “needle in a haystack.” The 17th‑century portrait had been misattributed for years, but experts now say it is unquestionably the work of the Dutch master. New research suggests popular GLP‑1 drugs like Ozempic and Wegovy may slightly increase the risk of osteoporosis and gout, according to an analysis of more than 146,000 adults with obesity and Type 2 diabetes. About 4% of GLP‑1 users developed osteoporosis vs. just over 3% of non‑users a 30% higher risk and gout rates were also modestly higher. Researchers say rapid weight loss and reduced nutrient intake may play a role, though the findings are not yet peer‑reviewed. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Une étude anglaise publiée ces derniers jours montre que les traitements injectables anti-obésité (Wegovy et Mounjaro) permettent bien de perdre beaucoup de poids... Mais pour peu de temps ! Seulement 18 mois après la fin du traitement, la plupart des patients avaient repris tout le poids perdu. En cette veille de journée mondiale contre l'obésité, notre spécialiste santé Agathe Landais fait le point sur ces traitements qui promettent une perte de poids rapide, et qui font fureur en Europe et aux Etats-Unis. Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed avec Agathe Landais du 03 mars 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

A Dutch museum has confirmed a newly rediscovered Rembrandt, thanks to a microscopic study that uncovered the artist’s signature touch a single, tiny brushstroke hidden like a “needle in a haystack.” The 17th‑century portrait had been misattributed for years, but experts now say it is unquestionably the work of the Dutch master. New research suggests popular GLP‑1 drugs like Ozempic and Wegovy may slightly increase the risk of osteoporosis and gout, according to an analysis of more than 146,000 adults with obesity and Type 2 diabetes. About 4% of GLP‑1 users developed osteoporosis vs. just over 3% of non‑users a 30% higher risk and gout rates were also modestly higher. Researchers say rapid weight loss and reduced nutrient intake may play a role, though the findings are not yet peer‑reviewed. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real cost of obesity drugs in the U.S. healthcare system.How much do GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro actually cost? Are they cost-effective in the long term? And can insurers and employers afford to provide them to millions of Americans living with obesity?If you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukProduced and presented by Sam Fenwick.Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small startup stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the weight-loss drug revolution, the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs.These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Picture: Person standing on weighing scales. Credit: Press Association)

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS. We're sharing details about the discovery of a new biomarker that not only confirms an MS diagnosis but also predicts the severity of an individual's disease course in the years ahead. We'll tell you about three studies focused on better managing some of the most common MS symptoms and funded by the International Progressive MS Alliance. And we'll explain how Merck and the Mayo Clinic are partnering to build a first-of-its-kind drug discovery platform using AI. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A GLP-1 for MS?  :22 I'm asking for your support:  1:31 Researchers discover biomarkers that can predict future disease course  2:13 The International Progressive MS Alliance invests $8.1 million in global studies that address the most common MS symptoms   5:44 Merck and the Mayo Clinic collaborate on AI-driven drug discovery platform  10:02 Dr. Ellen Mowry discusses the clinical trial to determine whether a GLP-1 drug can reduce inflammation in the central nervous system and offer neuroprotection to people with progressive MS  12:20 Share this episode  30:17 Next week  30:38 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/444 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms STUDY: Large-Scale Proteomics Across Neurological Disorders Uncovers Biomarker Panel and Targets in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/41747728 International Progressive MS Alliance https://progressivemsalliance.org JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 444 Guests: Dr. Ellen Mowry Privacy Policy

In this episode of the HAYVN Hubcast, Nancy Sheed welcomes back Katherine Saunders, co-founder of FlyteHealth, for a powerful conversation on the evolution of obesity and cardiometabolic care. Since her last appearance—when her company was still in its early stages under the name IntelliHealth—Katherine has led a transformation from a software-focused startup into a comprehensive virtual clinical care provider. Now rebranded as FlyteHealth, the company delivers integrated cardio-kidney-metabolic care directly to patients, while partnering with employers to reduce healthcare costs and improve outcomes. Katherine explains how the rise of GLP-1 medications like Wegovy, Ozempic, and Zepbound changed the national conversation around obesity. But she cautions against the current “GLP-1-only” mindset, emphasizing that true success requires comprehensive medical evaluation, personalized treatment plans, and ongoing support—not just a prescription. The discussion explores: Why obesity medicine was historically overlooked in medical training How GLP-1 demand has reshaped employer healthcare strategies The financial strain these medications place on self-insured employers Why fragmented healthcare leaves patients overwhelmed The importance of care navigation and communication between specialists How technology can enhance—not replace—the provider-patient relationship FlyteHealth's model blends advanced clinical decision support tools with human-centered care, allowing providers to practice at the top of their training while delivering better outcomes for patients and better ROI for employers. Key Highlights From Software to Full-Service Clinical CareFlyteHealth began as a tech platform to scale obesity treatment but evolved into a direct care provider when it became clear that technology alone wasn't enough. The GLP-1 Explosion — and Its LimitsWhile GLP-1 medications have revolutionized obesity treatment, Katherine stresses that medication without comprehensive care leads to poor outcomes and rising costs. The Employer Healthcare DilemmaSelf-insured employers face skyrocketing costs for GLP-1 medications. FlyteHealth offers a structured, outcomes-focused program that balances access with cost control. Obesity as a Root DiseaseTreating obesity improves or prevents over 200 related conditions, including hypertension, prediabetes, and cholesterol issues—making integrated care essential. Technology as a Support System, Not a SubstituteClinical decision support tools gather and analyze data before visits, allowing providers to spend more time educating and connecting with patients. This conversation highlights a pivotal moment in healthcare. The excitement around GLP-1 medications has brought long-overdue attention to obesity as a serious medical condition—but as Katherine makes clear, prescriptions alone are not the solution. Sustainable results require comprehensive care, personalized treatment, coordinated communication, and smart use of technology. FlyteHealth represents a model for where healthcare is heading: integrated, data-informed, and human-centered. As employer-sponsored healthcare continues to evolve and new therapies enter the market, thoughtful systems like this may be what keeps care both effective and financially sustainable. Connect with Nancy LinkedIn  Instagram Website Connect with Katherine LinkedIn Website Learn more about your ad choices. Visit megaphone.fm/adchoices

You can listen to the first episode of this three-part series here. GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one. Chris Hannay, The Globe's business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we'll explore access to these drugs with The Globe's health reporter Kelly Grant on who gets their GLP-1 covered by their insurance – and who doesn't. Plus, Globe audio producer Kasia Mychajlowycz leads us on a journey to understand just how the virtual pharmacies advertised all over her social media feed are vetting people who want Ozempic prescriptions. The next episode and final episode of Skinny, Inc. is next Monday, March 9. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Whole food plant-based diets are safer than GLP-1 drugs and more effective than reducing meat for long-term health. #ObesitySolutions #PlantBased #WeightLoss

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic from medical breakthroughs to real-life health impacts.Listeners, exciting news from Novo Nordisk: oral semaglutide at 25 milligrams, branded as Wegovy in pill form, delivered 16.6 percent weight loss in a newly published study. Apollo Pharmacy reports clinical trials showing average weight loss of 10 to 15 percent of body weight with semaglutide, and up to 20 to 22 percent with tirzepatide in some patients. The OASIS 4 Study Group in the New England Journal of Medicine found oral semaglutide 25 milligrams daily for 64 weeks led to about 11 percent more weight loss than placebo, around 26 pounds for a 234-pound person.According to the 2026 American Diabetes Association Standards of Care, preferred treatments for diabetes with overweight or obesity include glucagon-like peptide-1 receptor agonists like semaglutide or dual agonists like tirzepatide for their superior weight loss, cardiovascular, and metabolic benefits. These drugs suppress appetite, delay gastric emptying, and improve insulin sensitivity, mimicking bariatric surgery effects.Real-world data from HealthDay News and Epocrates shows satisfaction with semaglutide is driven by effective weight loss, with two-thirds of users reporting reduced appetite, cravings, or body weight, even though gastrointestinal side effects like nausea affect many. Rare concerns include motility disorders, but efficacy often outweighs them.A key caution from the STEP 1 trial extension in Diabetes Obesity and Metabolism: stopping semaglutide leads to significant regain, over 11 percentage points of lost weight by 120 weeks, as food noise returns. Physicians Committee for Responsible Medicine notes many regain two-thirds within a year, stressing long-term use or lifestyle transitions like daily habits to quiet cravings naturally.Oral Wegovy must be swallowed whole with no more than four ounces of water, 30 minutes before food or other meds, for full effect. It costs about 1350 dollars monthly, with prior authorizations likely.Stay tuned for more updates on these game-changers in weight management and health.Thank you listeners for tuning in. Please subscribe for weekly insights. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

The weight loss drug market is undergoing a dramatic transformation this week as Novo Nordisk announced major price cuts for its popular medications Ozempic and Wegovy. Starting January 2027, the Danish pharmaceutical company will reduce prices by up to 50 percent for Wegovy and 35 percent for Ozempic, with both medications selling for 675 dollars per month. This announcement reflects intensifying competition in the GLP-1 drug market, where Eli Lilly's Mounjaro and Zepbound have been aggressively capturing market share since their approval in 2022.The pricing pressure comes as Novo Nordisk faces multiple challenges despite the massive growth of the weight loss drug industry. Global sales of GLP-1 medications reached between 50 and 60 billion euros last year, with projections suggesting the market could hit 100 billion euros annually by the early 2030s. However, Novo Nordisk's share price has plummeted more than 60 percent in the past year, largely because the company can no longer charge premium prices in the United States, its most lucrative market. Additionally, the company's newly developed drug called CagriSema underperformed in clinical trials, achieving only 23 percent weight loss compared to Mounjaro's 25.5 percent.Meanwhile, Oprah Winfrey continues to be a prominent advocate for GLP-1 medications, discussing her personal experience with these drugs in various media appearances. According to her recent statements, Oprah began taking a GLP-1 medication in 2023 and lost approximately 50 pounds. When she stopped taking the medication after six months to test whether she could maintain the weight loss independently, she quickly regained 20 pounds and experienced a return of what she calls food noise, the constant mental preoccupation with eating. Oprah has emphasized that taking these medications appears to be a lifetime commitment, comparing it to managing other chronic conditions like high blood pressure. She has also noted an unexpected benefit, stating that the medication eliminated her desire for alcohol after years of heavy consumption. In her new book titled Enough, Your Health Your Weight and What It's Like to Be Free, Oprah explores her relationship with weight loss medications and discusses how obesity is now understood as a clinical disease rather than a personal failure.The price reductions announced this week signal that the intense competition in the GLP-1 market will continue to reshape the pharmaceutical landscape. As more variants and generic versions enter the market in coming years, prices are expected to decline further, potentially making these medications accessible to millions more people globally.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot AI.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

The State of Hormone & Peptide Industry with Phil Vela Disrupting the health & wellness industry. (2:15) "It's that hard to do IT, so it's that easy to succeed once you've done IT." (2:48) What he did before he started Vita Bella, and the origins of the company. (5:00) The most applicable skills gained from his previous career. (7:41) Calling out the 'Grey Market' and its competition. (9:44) The state of the peptide industry and the fallout with Transcend. (15:54) Results & service. (25:23) Breaking down the Vita Bella membership package. (30:07) Businessman at heart. (33:34) Why he believes it should be illegal to prescribe GLP-1s by themselves. (35:13) Bad actors giving bad guidance. (43:33) His outlook for the future of the industry. (45:14) Will Ozempic and Tirzepatide ultimately bankrupt the United States? (53:27) The importance and value of having a trainer while on a GLP-1. (56:47) "I didn't build this business for money. I built it for a legacy!" (59:07) "Newer" peptides that have been impressed by. (1:03:16) Rapid fire: The best peptide for… (1:11:56) Related Links/Products Mentioned Visit Vita Bella for an exclusive offer for Mind Pump listeners! ** The first 50 signups will get a Vita Bella welcome box. You can finally achieve a top 1% all-around health at an affordable price! ** Get 20% off Kion at getkion.com/mindpump ** No code needed automatically applied at check out! ** MAPS Great 8 Launch - (Retail $127, Code: LAUNCH for 50% off!) ** Launch bonus include: MAPS GREAT 8 Nutrition Guide. ** Visit: http://mapsgreat8.com/  Mind Pump Store Mind Pump Hormones Facebook Private Forum GLP-1 Litigation: Compounder Sues Eli Lilly, Novo Nordisk Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Federal Court Tosses Lilly's Suit Against Strive Pharmacy: Jurisdiction Still Matters Mind Pump #2125: Heal Like Wolverine: BPC 157 with Dr. William Seeds Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Phil Vella – "Philly" (@phillyvz) Instagram Jay Campbell (@jaycampbell333) Instagram Rick Niemi (@gods.economy) Instagram Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram    

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Today's episode of The Rizzuto Show might be the most “2026 energy” thing we've ever done — and that's saying something for a daily comedy show that thrives on chaos.First up: Liquid Death has created a $495 Bluetooth speaker urn called the “Eternal Playlist,” so when you're cremated, your ashes can keep vibing to Spotify. Yes, this is real. Yes, there's a stat about reducing your odds of haunting. And yes, Moon almost added it to his cart. We break down the marketing genius (or insanity), debate whether ghosts prefer classic rock or lo-fi beats, and ask the real question: who is this actually for?Then we dive headfirst into the wildest piece of funny celebrity gossip of the week. Bonnie Blue — an OnlyFans creator — claims she's pregnant after what she called a “breeding mission” involving 400 guys. Naturally, the internet immediately tagged Maury Povich. We discuss whether Maury should come out of retirement, whether we should host the paternity special ourselves in St. Louis, and how many DNA swabs King Scott is willing to sort through before lunch. It's entertainment gossip meets absurd reality TV, and somehow it only gets weirder.As if that wasn't enough, the Rock and Roll Hall of Fame nominations dropped, and the studio turned into a full-blown debate club. Wu-Tang Clan. Sade. Oasis. Mariah Carey. Does the Rock Hall still matter? Does any award show? Do artists secretly care even when they pretend they don't? It's sarcastic humor, passionate music arguments, and classic Rizz Show energy all rolled into one.This episode is peak funny podcast chaos — part comedy podcast, part music nerd fight, part daily humor therapy session for St. Louis and beyond. If you love pop culture commentary, comedy news, weird headlines, and the kind of daily show that spirals off topic in the best possible way, this one's for you.And yes… we still want to know who's buying that urn.Follow The Rizzuto Show → https://linktr.ee/rizzshow for more from your favorite daily comedy show.Connect with The Rizzuto Show Comedy Podcast online → https://1057thepoint.com/RizzShow.Hear The Rizz Show daily on the radio at 105.7 The Point | Hubbard Radio in St. Louis, MO.Heart Attack Grill 'spokesman' dies after apparent heart attackThe car with $8,660 in tickets that nobody will towWhat is sepsis, developed by UK woman who lost 4 limbs, after dog lick?What Does It Mean When a Dog Paws You? Decoding Your Canine's CommunicationDeath isn't the end: Meta patented an AI that lets you keep posting from beyond the graveNovo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027‘Plastic Eating' Trend for Weight Loss Is Going Viral in ChinaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Een jaar lang scheten aandeelhouders van Wolters Kluwer in hun broek voor wat er daar aan zat te komen. Het verdienmodel van het databedrijf zou onderuit gehaald worden door AI-bedrijven die het allemaal beter en sneller gaan kunnen. Waardoor de beurskoers in een jaar tijd met ruim 60 procent daalde. Alleen... dat blijkt nu behoorlijk paniekvoetbal. De kwartaalcijfers laten namelijk een ander beeld zien. Omzet en winst stijgen. En Wolters Kluwer bewijst het ongelijk van beleggers nog even extra: want vooral de cloud-activiteiten groeien hard, met 15 procent. Een afscheid in stijl voor ceo Nancy McKinstry, wiens laatste kwartaal dit was. Deze aflevering kijken we of aandeelhouders die zijn vertrokken, nu reden hebben om terug te keren.Hebben we het ook over een ander beursdrama, maar dan in Denemarken. Dat van Novo Nordisk. De maker van onder meer Ozempic had een voorsprong met hun afvalmedicatie, maar werd keihard ingehaald door de concurrentie. En zag het aandeel zelf op een crashdieet gaan. Van het meest waardevolle Europese beursbedrijf, naar een van de beurslosers. Maar die tijd is misschien wel voorbij, want Novo Nordisk heeft iets verzonnen. Het gaat de prijzen halveren.Hoor je ook meer over de State of the Union. Trumps speech heeft een record gebroken. Nog nooit duurde dat politieke praatje zo lang. Maar of het ook een beetje inhoudelijk was, dat bespreken we deze aflevering. Zo wil Trump de inkomstenbelasting inruilen voor.... tarieven! Te gast: Martine Hafkamp van Fintessa Vermogensbeheer BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion.  Everything is coming up Lilly. The Indianapolis-based pharma bested its chief rival, Novo Nordisk in a head-to-head test. In a Phase 3 trial initiated by Novo itself, Lilly's Zepbound generated 25.5% weight loss while the Danish pharma's CagriSema elicited 23%. The results sent Novo's shares plummeting by an unprecedented 20% to a pre-Wegovy valuation while Lilly's market cap continues to climb.   Novo attempted a comeback on Tuesday, announcing that its triple-G agonist UBT251 scored almost 20% weight loss after 24 weeks in a Phase 2 trial in China. By comparison, Lilly's own triple-G competitor retatrutide led to 17.5% weight loss over the same timeframe, according to BMO Capital Markets analysts. Novo also sweetened the pot, announcing that it would slash the prices for all three of its GLP-1 medicines starting in 2027.    Meanwhile, the FDA kicked off Rare Disease Week with draft guidance on the new Plausible Mechanism Pathway for personalized therapies that was first teased in November. Jumping off last summer's Baby KJ success story, the new pathway is aimed at advancing treatments for ultra-rare diseases. And a bipartisan senate hearing on Thursday will focus on the authorization process for rare disease therapies.  While the rare disease space has enjoyed recent regulatory progress, funding these vital therapies remains a challenge. Companies like the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech, are trying to change this with creative approaches including tax exempt status and unique partnerships with CDMOs and CMOs. Finally, in a move that also has implication for the rare disease space, the FDA's official pivot from a two clinical trial requirement to just one for new drug applications is lighting up biopharma social media.   And over at the CDC, there is more upheaval on the leadership front as National Institutes of Health Director Jay Bhattacharya replaces acting director Jim O'Neill as head of the agency, and principal deputy director Ralph Abraham steps down, citing “unforeseen family obligations.”    On the business front, Gilead inked the biggest M&A deal of the year so far, acquiring CAR T partner Arcellx for nearly $8B. And Merck's Keytruda should have a few extra years of dominance thanks to a web of patents, with billions on the line. Check it out in BioPharm Executive, in your inboxes Wednesday.  HostsJef Akst, Managing Editor, BioSpaceHeather McKenzie, Senior Editor, BioSpaceAnnalee Armstrong, Senior Editor, BioSpace

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

How Sesame Can Offer the Wegovy Pill at Cash-Pay Prices Dr. Michael Botta, President and Co-founder of Sesame, shares details of their newly announced partnership to offer the Wegovy pill, their continued relationship with Costco, how their clinicians approach patients who are loading their medical records to ChatGPT, and more insights from the quickly expanding cash pay side of healthcare.  All that, plus the Flava of the Week about the health at home waiver being extended for five more years. Now that these programs have the certainty they've been fighting for, how can we advocate for the innovations that leaders have been asking for all along? Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Are you worried GLP-1 medications will make coaches obsolete? Medications like Ozempic, Wegovy, and Mounjaro are changing the weight loss conversation, but they're not replacing the work coaches do. In fact, they're making behavior change coaching more essential than ever.In this episode, Dr. Kasey Jo Orvidas breaks down what GLP-1s actually do, why 50-75% of users stop taking them within a year, and how coaches can support clients using these medications while staying ethically grounded and professionally valuable.You'll learn:What GLP-1 medications actually do (and what they don't teach clients about behavior change, mindset, or long-term habits)Why people still need coaches even when medication accelerates weight lossHow to navigate the ethical dilemma of posting client transformations when GLP-1 use is involvedSix ways coaches can support clients on GLP-1s, from muscle preservation to managing identity shifts and shameWhy the future of coaching requires more psychology, communication skills, and mindset work (not less)Watch the full episode on YouTube: https://youtu.be/gKmAYVkVbDgRegister for my FREE 3-Day Training: The Coaching CodeConnect with me on Instagram! Grab 5 Free Lessons in Mindset and Behavior Change Coaching [HMCC WAITLIST]LEAVE A REVIEW, WIN A WORKSHOP! After you leave your review, take a screenshot and upload it to this form to be entered to winWant me to answer your questions on my next Q&A episode? Drop your questions here!Related Topics: GLP-1 medications for weight loss, Ozempic and coaching, Wegovy and fitness coaches, coaching clients on weight loss medication, behavior change coaching, mindset coaching with GLP-1s, ethical coaching practices, client transformation ethics, future of health coaching, weight loss medication support, coaching industry trends, muscle preservation on GLP-1s, sustainable weight loss habits

The Science Behind the New Wegovy Pill (with Novo Nordisk's Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn't random—it's part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

What if weight loss isn't about discipline—but about biology? In this episode of Healthy Looks Great on You, Dr. Vickie welcomes Dr. Suzanna Chatterjee-Morris, a board-certified OB-GYN and obesity medicine physician, for a fascinating conversation about GLP-1 medications and what they really do inside the body. Together, they take listeners to mini medical school to break down: What GLP-1 medications are and how they affect insulin resistance and metabolism Why weight gain is often a medical issue—not a personal failure How GLP-1s are being used beyond weight loss, including PCOS, infertility, fatty liver disease, sleep apnea, and cardiovascular health What the research shows about long-term benefits and reduced all-cause mortality Common concerns like muscle loss, weight regain, and “Ozempic face” Why nutrition, protein intake, and exercise are essential when using these medications Dr. Chatterjee also explains the concept of weight “set point,” why stopping these medications too soon often leads to regain, and how GLP-1s work best when paired with sustainable lifestyle changes—not willpower alone. If you've been curious or confused about Ozempic, Wegovy, Zepbound, or similar medications, this episode offers clarity, evidence, and reassurance—without hype or shame.

Queda de cabelo, fraqueza e intestino parado. Vamos falar do preço metabólico da falta de nutrientes e como reverter isso.Bônus: Suplementos que podem ajudar para quem estiver usando GLP-1Se você está usando análogos de GLP-1 (como Ozempic, Mounjaro, Wegovy) para emagrecer, é provável que esteja feliz com os números caindo na balança, mas... exausta na vida real.Sabe aquela sensação de corpo pesado? De fraqueza para subir um lance de escada? Aquele cabelo caindo mais que o normal e uma “névoa” mental que não passa?Não, não é “coisa da sua cabeça”. E não vale colocar na conta da menopausa também não. E não, não é o preço que você precisa necessariamente pagar para ser magra — se souber fazer direito.Compreenda por que emagrecer sem suporte metabólico leva à magreza frágil, ao efeito rebote e ao colapso da vitalidade. E, principalmente, como usar essas medicações do jeito certo, com estratégia, nutrição e proteção muscular.Neste episódio, você vai aprender:Por que estar magra não significa estar saudávelComo a perda de apetite leva ao modo racionamento metabólicoO risco real da perda muscular silenciosa com GLP-1Por que perder músculo acelera o envelhecimento e o efeito reboteO impacto das “canetinhas” no intestino, digestão e SIBOComo fazer o uso correto dos GLP-1 com suporte metabólicoEstratégias de proteína, treino e suplementação para preservar energiaComo reverter cansaço, fraqueza, queda de cabelo e intestino paradoMeu livro Perimeno Quê? O manual que eu queria ter tido quando eu passei pela perimenopausa já está disponível para vendas.

Millions of Americans are turning to GLP-1 weight loss medications like Ozempic and Wegovy. But here's the question few are asking: What happens when you stop? Research shows that many people regain a significant portion of the weight within a year of discontinuing GLP-1 medications. In some studies, participants regained as much as two-thirds of the weight they lost. On this episode of The Exam Room, Chuck Carroll sits down with world-renowned obesity researcher James Hill, PhD to unpack the real story behind long-term weight management after GLP-1 medications. Dr. Hill is a pioneering scientist and former president of The Obesity Society and The American Society for Nutrition. Along with Dr. Holly Wyatt, he co-authored the new book Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight. In this conversation, you'll learn: • Are GLP-1 medications meant to be long-term? • What happens inside the body when you stop taking them • Why so many people regain weight after discontinuing • The 10-week transition strategy for maintaining weight loss • The three types of weight regain—and how to avoid each • How to quiet food noise and cravings naturally • Daily habits that can replace the work of GLP-1 medications Chuck also shares his personal perspective on long-term weight loss success, including: • What he's learned after weight loss surgery • The lifestyle shifts that made his results sustainable • And what he wishes he knew before surgery that he knows now If you're considering GLP-1 medications, currently using them, or thinking about stopping, this episode could change how you approach weight maintenance forever.

U.K. authorities on Thursday arrested Andrew Mountbatten-Windsor on suspicion of "misconduct in public office." Police had previously said they were investigating whether the former prince sent confidential trade documents to the late sex offender Jeffrey Epstein. Liz Stein, a survivor of Epstein's abuse and an anti-trafficking advocate, joins us.Then, Meta's Mark Zuckerberg appeared in a Los Angeles court on Wednesday to defend his company against a lawsuit that alleges social media harms children. LA Times reporter Sonja Sharp breaks down the trial so far.And, GLP-1 medications could help treat alcohol and drug addiction, experts say. Addiction specialist Dr. Mark S. Gold explains how medications such as Ozempic and Wegovy are prompting "a reconceptualization of addiction itself."Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this conversation with Dr. Wendy Oliver-Pyatt, a board-certified psychiatrist specializing in eating disorders and founder of Within Health and Galen Hope treatment centers, Karena explores the life-threatening reality of eating disorders as serious mental illnesses that claim one life every 52 minutes in America. Dr. Oliver-Pyatt explains the biopsychosocial foundations of eating disorders, shares her personal journey from ballerina to eating disorder specialist, and discusses the warning signs in athletes and high achievers. She reveals the controversial truth about GLP-1 medications and eating disorder risk, and provides actionable tools for reframing your relationship with your body through self-compassion and intentional self-care practices.How do you stop fighting your body and start healing your relationship with food, weight, and self-worth?Understanding that weight stigma is trauma opens the door to compassion—and real recovery.(01:13) The Deadliest Mental Illness You've Never Heard OfEating disorders kill one person every 52 minutes in AmericaWhy they aren't classified with "serious" mental illnesses despite being more lethal than manyThe confusion between societal pressure and actual mental illness diagnosisUnderstanding the biopsychosocial foundation: biological, psychological, social, and spiritual factors(04:47) From Ballerina to Eating Disorder PsychiatristGrowing up as the child of a Holocaust survivor with a mildly autistic motherHow ballet and puberty collided to create impossible body standardsThe danger of narrow frameworks about what's "acceptable" in our bodies(18:32) Athletes, Perfectionism & the "Healthy" Eating TrapWhy high-achieving athletes and fitness enthusiasts face elevated eating disorder riskThe difference between disordered eating behaviors and diagnosable eating disordersHow orthorexia disguises itself as "clean eating" or "wellness"Warning signs to watch for in competitive sports and fitness culture(32:47) What Real Treatment Looks LikeThe biopsychosocial-spiritual treatment model that addresses all aspectsHow nutritional rehabilitation and medical stabilization work togetherFamily-based treatment approaches for adolescents and young adults(47:36) The GLP-1 Controversy: Ozempic, Wegovy & Eating Disorders"It's asinine there's no eating disorder warning"How rapid weight loss medications trigger and worsen eating disorders, especially in teensThe danger

“That's the thing that's maybe getting lost in some of the fear mongering around it is that, it's not the easy way out. It doesn't mean that you don't have to do the work. It means that when you do the work, the work actually makes the difference.” —Aja BeckettFood noise can sit in the back of the mind all day, from planning the next meal at breakfast to carrying quiet shame after every snack. In a culture that moralizes weight and labels bodies as failures, real medical treatment for obesity often gets buried under hot takes about shortcuts and cheating. This conversation brings the lived reality of GLP-1 medication into the light, with honesty about both relief and responsibility.Aja Beckett shares decades of struggling with obesity, endless diets, and that constant mental hum around food, then walks through how starting a GLP-1 weight loss drug shifted cravings, energy, and hope. Her experience led to building Shotsy, a companion app that tracks doses, side effects, and progress for people on GLP-1 medications.Press play to hear how this new class of medications is reshaping daily life, mindset, and digital tools around obesity care, including:What GLP-1 drugs like Ozempic and Wegovy actually do in the bodyThe difference between “food noise” and genuine hungerWhy weight loss drugs are not a lazy shortcut or moral failureHow mental health, cravings, and compulsive behaviors often change on GLP-1sThe cost, access, and safety concerns around weight loss injections and pillsHow a GLP-1 tracking app grew from one person's spreadsheet into a fast-growing productWhat long-term obesity treatment and maintenance can realistically look likeConnect with Heather:WebsiteLinkedInInstagramFacebookYouTubeEpisode Highlights:01:11 Meet Aja Beckett: Founder of Shotsy & GLP‑1 Success Story04:43 Discovering Ozempic & a Difficult Doctor's Visit07:35 Beyond Weight Loss: GLP‑1, Mental Health & Addictive Behaviors10:43 Losing 90 Pounds: From Obesity to Healthy BMI13:30 Do You Still Have to Eat Healthy & Work Out on GLP‑1?16:21 When the Food Noise Stops: First Days on GLP‑119:37 Super Bowl Snacks, Portion Control & Balanced Indulgence22:12 Body Dysmorphia in Bigger & Smaller Bodies26:00 Safety vs Affordability: Regulation, Shortages & DIY Risks32:09 Introducing Shotsy: The GLP‑1 Companion App Idea39:50 Why Tools Like Shotsy Matter for Accountability & Tracking42:21 GLP‑1 Isn't the “Easy Way Out”: Doing the Work & Seeing ResultsResources:

Dhruv Khullar, practicing physician, associate professor of health policy and economics at Weill Cornell Medical College and contributing writer at The New Yorker, talks about the effect GLP-1 drugs, like Ozempic, are having on curbing addictions and what researchers are studying about that phenomenon.Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images

Are medications solving the root of metabolic disease — or just masking it? In this powerful episode that started as a Instagram LIVE, I break down what you're not being told about the most commonly prescribed drugs for blood sugar, cholesterol, and weight loss: GLP-1s (Ozempic, Wegovy), statins, and Metformin. I help you unpack: What these medications actually do (mechanisms of action) The real data behind their risk reduction claims How statins may suppress natural GLP-1 production Why GLP-1s cause significant muscle loss, not just fat loss Why Metformin doesn't reverse insulin resistance More importantly, I walk you through what does restore metabolic health — including a system that's helping real people normalize labs, lose weight, and feel better without long-term prescriptions. What You'll Learn: The surprising truth about how statins impact your gut hormones Why insulin resistance — not cholesterol — is the real root cause How GLP-1 drugs work and what happens when you stop them The 3-step system to support blood sugar and cholesterol naturally How to evaluate your labs beyond A1C and LDL Resources Mentioned: Join my 90-Day Insulin Reset: Comment RESET on Instagram or Facebook and I'll DM you the link- https://shanahussinwellness.com/programs-courses/reset/ Feel Great Nutraceuticals: The first step to restoring insulin and liver function- https://shanahussinwellness.com/programs-courses/feelgreat/ Connect with Shana: Instagram: @shana.hussin.rdn Website: shanahussinwellness.com Facebook: Shana Hussin Wellness

Send a textWegovy's new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn't which drug helps you lose more weight—it's which one treats your underlying metabolic disease more effectively.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

 Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.comHave you ever wondered which weight loss medication is actually right for you? With so many options out there—new GLP-1 medications like Wegovy and Zepbound, oral versions hitting the market, and older prescriptions—it can feel totally overwhelming.In this episode, we break it all down: how much weight you might realistically lose, how other health conditions factor in, cost considerations, who should avoid certain medications, and even how combination therapy can sometimes make sense.Over the years, I've covered these topics in different ways. One of my favorite episodes was with Dr. Angela Fitch, where we explored all the available medications at that time. Since then, new therapies like Zepbound and oral Wegovy have emerged, changing the landscape even more. This episode isn't meant to replace a one-on-one conversation with an obesity expert—that's still the gold standard—but it gives the information you need to start thinking about what might fit your goals, your body, and your lifestyle.By the end, you'll have a clearer picture of how these medications work, who they help most, and how to approach the decision thoughtfully and safely. Obesity is a medical condition, and like any condition, it deserves expert care—so let's dive into your options.Topics Covered:How Much Weight Can You Really Lose on GLP-1 Medications?The Other Medications That Still Play a Role in Weight LossWegovy vs. Zepbound: How Much Weight Loss Do You Actually Need?Why Weight Loss Is a Struggle—and How the Right Medication Makes the DifferenceResults Matter—But So Does the Price TagWho Should Avoid Certain Weight Loss MedicationsChoosing the Right Weight Loss Medication: Pills, Injections, and Personalized ApproachesDo You Really Need More Weight Loss?By the end of this episode, you'll have a clear understanding of the different weight loss medications, how they work, who they help most, and what to consider when choosing the right approach for your goals and health.For a deeper dive into each medication, real-world results, and expert insights on tailoring a plan that's safe, sustainable, and effective, the full episode is ready for you—it's packed with everything you need to make an informed decision about your weight loss journey.Referenced Episodes:Can a test tell me if Wegovy or Zepbound will work for me? With Dr.Andres Acosta of PhenomixMedications for Weight Loss with guest, Dr. Angela Fitch,Phentermine and Qsymia - What You Need to Know About These Weight LossOral Wegovy: All You Need to Know About This New Medication, with Joseph ZucchiConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

On Food Talk with Dani Nierenberg, Dani speaks with Ndidi Okonkwo Nwuneli, the President and CEO of the ONE Campaign. They discuss how the dismantling of the U.S. Agency for International Development has impacted the African continent, the opportunities this shifting landscape creates for the emergence of African-led solutions, and the innovative women spearheading food and agriculture systems transformation. Plus, hear about the recent extension of the African Growth and Opportunity Act, severe storm damage in Portugal and Spain causing hundreds of millions of euros in agricultural losses, new recommendations from the World Resources Institute for retailers to help reduce household food waste, and a looming strike at the JBS meatpacking plant in Colorado over alleged inhumane working conditions. Dani also discusses GLP-1 drugs like Ozempic and Wegovy, noting their complex and under-researched impact on people with eating disorders, including both potential benefits and serious risks. While you're listening, subscribe, rate, and review the show; it would mean the world to us to have your feedback. You can listen to "Food Talk with Dani Nierenberg" wherever you consume your podcasts.

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Finding Freedom, host John Odermatt examines the rise of GLP-1 drugs like Ozempic and Wegovy, exploring how they work by overriding the body's natural hunger signaling through synthetic peptides inspired by Gila monster venom. While acknowledging these medications have legitimate applications for severe obesity and diabetes, John raises concerns about FDA-listed side effects including muscle loss, stomach paralysis, and thyroid tumor warnings, especially as Trump's new RX.gov platform makes these drugs more affordable and accessible. Drawing from his personal experience losing 50 pounds and maintaining the weight loss, John argues that synthetic GLP-1s don't address root metabolic dysfunction caused by poor diet, sedentary lifestyle, and chronic inflammation. He advocates for natural alternatives like berberine, chromium polynicotinate, and polydextrose fiber that support the body's own GLP-1 production rather than overriding it. John emphasizes the importance of building sustainable habits through diet, exercise, and supplementation that restore metabolic function instead of creating pharmaceutical dependency. The episode concludes with a call to prioritize long-term health over quick fixes, warning that rapid weight loss without muscle maintenance could lead to premature aging and sarcopenia. CHAPTERS: 0:00 - Introduction: GLP-1 Drugs Overview0:54 - Welcome & Episode Preview1:16 - Sponsor: Fox and Sons Coffee2:18 - John's Personal Weight Loss Journey4:49 - Trump RX.gov Announcement & Concerns10:22 - What is GLP-1? Understanding the Science13:46 - FDA-Listed Side Effects & Risks17:12 - Root Causes of Metabolic Dysfunction20:22 - Natural Alternative #1: Berberine22:32 - Natural Alternative #2: Chromium Polynicotinate23:34 - Natural Alternative #3: Polydextrose Fiber27:15 - Lifestyle Balance & Sustainable Habits30:29 - The Danger of Quick Fixes31:47 - Natural Supplements Recap & Resources34:45 - Final Thoughts & Call to Action36:33 - Support Lions of Liberty LINKS: John Odermatt on Twitter: @JohnOdermattJohn Odermatt on Instagram: @JohnOdermattEmail: John@LionsofLiberty.comNewsletter: https://john-odermatt-finding-freedom.kit.com/105b53c794Trump RX.gov: https://trumprx.gov SPONSOR: This episode is brought to you by Fox and Sons Coffee – fresh, high-quality coffee shipped directly to your door, available as whole bean or ground to your preference. Get 15% off orders of $40 or more with promo code JOHN at checkout.Visit: FoxNSons.com SUPPORT LIONS OF LIBERTY: Help keep this podcast going! We rely on listener support to continue bringing you content on health, freedom, and personal empowerment.Support us on Patreon: https://patreon.com/lionsoflibertySupport us on Locals: https://lionsofliberty.locals.com/Subscribe, rate, and review wherever you listen – it makes a huge difference! Learn more about your ad choices. Visit megaphone.fm/adchoices